James la Rocque, MD
Endocrinology, Diabetes & Metabolism · Chesapeake, VANPI 1659462398
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.6% of the total across 780 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 49 manufacturers, the largest accounting for just 10.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $3,546 and has fallen 50.5% since, to $1,757 in 2025. Among endocrinology, diabetes & metabolism clinicians in VA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 780 payments — averaging $22.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Corcept Therapeutics$2K
- Lilly USA, LLC$2K
- Amgen$1K
- AstraZeneca$1K
- Novo Nordisk$1K
- Sanofi-aventis U.S. LLC$1K
- plus $9K from 43 others
Across 216 payments — averaging $2591.74 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$347K
- Novo Nordisk AS$92K
- AbbVie$61K
- Medtronic$44K
- Kowa Research Institute, Inc.$12K
- Sanofi US Services Inc.$5K
What the payments were for
- Travel & lodging$8275%
- Food & beverage$16,15393%
- Education$4613%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$17,440 in reported general payments places this provider in the 90th percentile of 223 endocrinology, diabetes & metabolism providers in Virginia.
See all endocrinology, diabetes & metabolism providers in Virginia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KorlymMifepristone | 15 | $621,203 |
| OzempicSemaglutide | 293 | $573,023 |
| TrulicityDulaglutide | 289 | $541,784 |
| JardianceEmpagliflozin | 366 | $441,856 |
| Signifor LarPasireotide Pamoate | 12 | $224,576 |
| FarxigaDapagliflozin Propanediol | 163 | $206,189 |
| JanuviaSitagliptin Phosphate | 112 | $153,744 |
| ForteoTeriparatide | 24 | $104,258 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 45 | $102,710 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 525 | $97,587 |
| MounjaroTirzepatide | 53 | $95,557 |
| Humalog Kwikpen U-100Insulin Lispro | 178 | $87,467 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 101 | $71,520 |
| Bydureon BciseExenatide Microspheres | 28 | $58,997 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 83 | $54,929 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Forteo, Mounjaro, Humalog | $1,662 | $770,795427 claims |
| Novo NordiskOzempic, Novolog, Rybelsus, Fiasp | $1,167 | $652,313396 claims |
| Corcept TherapeuticsKorlym | $1,836 | $621,20315 claims |
| Boehringer IngelheimJardiance, Tradjenta | $422 | $474,875399 claims |
| MerckJanuvia, Janumet Xr, Janumet | $301 | $231,277210 claims |
| Recordati_rare_diseases_inc.Signifor Lar | $368 | $224,57612 claims |
| AstraZenecaFarxiga | $1,172 | $206,189163 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $1,055 | $30,12812 claims |
| AbbVieSynthroid | $713 | $18,518234 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $471 | $10,228855 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 223 endocrinology, diabetes & metabolism providers in Virginia.
Other endocrinology, diabetes & metabolism in Chesapeake
- Cesar Plazas-GuzmanChesapeake$14K
- Danielle CastilloChesapeake$11K
- Bindiya MagoonChesapeake$8K
- Farhad ZangenehSterling$1.2M
- James MulindaRoanoke$788K
- Jeffrey SicatGlen Allen$657K
- Dewey BaileyRoanoke$645K
- Domenica RubinoArlington$608K
- Samamtha HudsonMidlothian$372K
- Elias SirajNorfolk$316K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.